Ally Bridge Group’s Compass Therapeutics CMPX Stock Holding History

Ally Bridge Group’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.29M	Buy	+1,000,000	New	+$5.77M	4.27%	9

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ally Bridge Group's CMPX Position: Q1 2024 in Review

Ally Bridge Group sold out of Compass Therapeutics (CMPX) in Q1 2024, closing a stake of 834,630 shares — an estimated $1.3M sold.

Ally Bridge Group first reported a position in CMPX in Q2 2023 and held it in 3 quarters. The position peaked at $2.91M in Q2 2023. 78 funds tracked by Wall St. Rank hold CMPX as of Q1 2024.

Ally Bridge Group reported no remaining Compass Therapeutics position as of Q1 2024 after selling out during the quarter.
Ally Bridge Group sold 834,630 Compass Therapeutics shares in Q1 2024, an estimated $1.3M.
Ally Bridge Group first reported a position in Compass Therapeutics in Q2 2023 and held it in 3 quarters.
Ally Bridge Group's Compass Therapeutics position peaked at $2.91M in Q2 2023.
78 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2024.

Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.